Hyoscyamine Sulfate
Failed Content Uniformity Specifications: resulting in both superpotent and subpotent tablets.
Class I is the FDA's most serious recall category: a reasonable probability that using the product will cause serious health consequences or death. It is a small share of all recalls, but the one to check first if a medication you take appears here.
1,750 recalls, newest first.
Failed Content Uniformity Specifications: resulting in both superpotent and subpotent tablets.
Failed Content Uniformity Specifications: resulting in both superpotent and subpotent tablets.
Failed Content Uniformity Specifications: resulting in both superpotent and subpotent tablets.
Labeling; Label Mixup; box labeled to contain 200 mg blister packs but actually contain 100 mg blister packs
Non Sterility; contaminated with Klebsiella pneumoniae
Presence of particulate matter: Confirmed customer report for the presence of particulate matter within a single vial.
Non-Sterility; microbial contamination identified as Bacillus circulans
Microbial Contamination of Non-Sterile Products: contamination with the bacteria, Burkholderia cepacia.
Microbial Contamination of Non-Sterile Products; microbial contamination with B. cepacia
Defective Container: Incomplete seal on blister packaging, leading to tablet swelling and enlarging due to effervescence process beginning as oxygen and moisture enter the blister packaging.
Microbial contamination of Non-Sterile Products; positive findings of Burkholderia cepacia
Marketed without an approved NDA/ANDA: FDA sample analyses revealed the presence of undeclared sildenafil and/or its analogs in products marketed as dietary supplements
Marketed without an approved NDA/ANDA: FDA sample analyses revealed the presence of undeclared sildenafil and/or its analogs in products marketed as dietary supplements
Marketed without an approved NDA/ANDA: FDA sample analyses revealed the presence of undeclared sildenafil and/or its analogs in products marketed as dietary supplements
Marketed without an approved NDA/ANDA: FDA sample analyses revealed the presence of undeclared sildenafil and/or its analogs in products marketed as dietary supplements
Marketed without an approved NDA/ANDA - presence of undeclared sibutramine.
Marketed without an approved NDA/ANDA - presence of undeclared sildenafil.
Non-sterility - presence of bacteria confirmed by outside laboratory after day 14.
Labeling: Label Error on Declared Strength. Product has correct label on the syringe and the case but some units are incorrectly labeled as .4 mg/10 mL (40 mcg/ml) on the light protective overwrap of each syringe.
Labeling: Label Mix-Up: Products labeled Biotin 100 mg found to contain 4-aminopyridine
Non-Sterility: fungal contamination due to leaking containers.
Presence of Particulate Matter: Confirmed customer complaint for the presence of particulate matter.
Presence of Particulate Matter: particulate matter identified as an insect in one vial.
Presence of Particulate Matter: particulate matter identified as glass in one vial.
Super-Potent Drug: Out of specification for potency results (high) were obtained for one lot of morphine sulfate Inj.